Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). Adicet Bio was founded in late 2015 with significant investment from OrbiMed, Novartis Venture Funds and Pontifax. In August 2016, Regeneron and Adicet Bio announced a strategic collaboration to discover and develop next-generation engineered immune-cell therapeutics and in September 2016, Adicet Bio was recognized and named by FierceBiotech as a “Fierce 15” Biotech Company of 2016

Contact Adicet Bio
Visit Website